Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KZR Kezar Life Sciences	$4.44 +4.0%	$4.30	$3.62 ▼ $9.18	$32.44M	0.58	52,690 shs	46,562 shs
NMRA Neumora Therapeutics	$0.76 -5.3%	$0.76	$0.61 ▼ $17.19	$122.43M	2.73	1.53 million shs	10.84 million shs
RAPT Rapt Therapeutics	$8.43 -13.4%	$7.66	$5.67 ▼ $30.60	$139.40M	-0.11	164,935 shs	592,962 shs
SCPH scPharmaceuticals	$3.87 -2.8%	$3.30	$1.94 ▼ $5.65	$204.31M	0.36	372,368 shs	688,056 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KZR Kezar Life Sciences	+3.98%	-1.77%	+9.90%	-9.76%	-29.65%
NMRA Neumora Therapeutics	-5.32%	-3.67%	+5.80%	-26.51%	-91.20%
RAPT Rapt Therapeutics	-13.36%	+13.46%	+8.31%	-13.63%	-65.45%
SCPH scPharmaceuticals	-2.76%	+0.78%	+8.10%	+39.21%	-12.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KZR Kezar Life Sciences	4.3998 of 5 stars	3.2	3.0	4.6	3.3	2.5	0.6
NMRA Neumora Therapeutics	2.5085 of 5 stars	3.1	1.0	0.0	2.8	2.5	1.3
RAPT Rapt Therapeutics	4.1909 of 5 stars	3.2	3.0	4.2	1.9	1.7	1.3
SCPH scPharmaceuticals	4.5092 of 5 stars	3.5	4.0	4.2	3.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KZR Kezar Life Sciences	2.33	Hold	$39.50	789.64% Upside
NMRA Neumora Therapeutics	2.22	Hold	$9.29	1,126.81% Upside
RAPT Rapt Therapeutics	2.33	Hold	$24.00	184.70% Upside
SCPH scPharmaceuticals	3.00	Buy	$14.00	261.76% Upside

Current Analyst Ratings Breakdown

Latest KZR, NMRA, SCPH, and RAPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2025	RAPT Rapt Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $8.00
5/22/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$48.00
5/13/2025	NMRA Neumora Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/10/2025	NMRA Neumora Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/2/2025	NMRA Neumora Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Underperform	$7.00 ➝ $1.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KZR Kezar Life Sciences	$7M	4.64	N/A	N/A	$16.02 per share	0.28
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
RAPT Rapt Therapeutics	$1.53M	91.13	N/A	N/A	$11.51 per share	0.73
SCPH scPharmaceuticals	$36.33M	5.62	N/A	N/A	$0.27 per share	14.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KZR Kezar Life Sciences	-$83.74M	-$10.82	N/A	N/A	N/A	N/A	-61.15%	-50.27%	8/12/2025 (Estimated)
NMRA Neumora Therapeutics	-$243.79M	-$1.61	N/A	N/A	N/A	N/A	-84.79%	-77.57%	8/5/2025 (Estimated)
RAPT Rapt Therapeutics	-$129.87M	-$19.20	N/A	N/A	N/A	N/A	-81.47%	-70.24%	8/6/2025 (Estimated)
SCPH scPharmaceuticals	-$85.15M	-$1.91	N/A	N/A	N/A	-216.24%	-594.07%	-73.54%	8/13/2025 (Estimated)

Latest KZR, NMRA, SCPH, and RAPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SCPH scPharmaceuticals	-$0.28	-$0.34	-$0.06	-$0.37	$11.63 million	$11.75 million
5/13/2025	Q1 2025	KZR Kezar Life Sciences	-$2.56	-$2.27	+$0.29	-$2.27	N/A	N/A
5/12/2025	Q1 2025	NMRA Neumora Therapeutics	-$0.40	-$0.42	-$0.02	-$0.42	N/A	N/A
5/8/2025	Q1 2025	RAPT Rapt Therapeutics	-$2.48	-$0.64	+$1.84	-$0.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A
SCPH scPharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KZR Kezar Life Sciences	0.04	7.09	7.09
NMRA Neumora Therapeutics	N/A	8.98	8.98
RAPT Rapt Therapeutics	N/A	21.11	21.11
SCPH scPharmaceuticals	3.86	5.48	4.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KZR Kezar Life Sciences	67.90%
NMRA Neumora Therapeutics	47.65%
RAPT Rapt Therapeutics	99.09%
SCPH scPharmaceuticals	89.52%

Insider Ownership

Company	Insider Ownership
KZR Kezar Life Sciences	10.40%
NMRA Neumora Therapeutics	26.80%
RAPT Rapt Therapeutics	2.36%
SCPH scPharmaceuticals	4.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KZR Kezar Life Sciences	60	7.31 million	6.55 million	Not Optionable
NMRA Neumora Therapeutics	108	161.75 million	118.40 million	Optionable
RAPT Rapt Therapeutics	80	16.54 million	16.15 million	Optionable
SCPH scPharmaceuticals	30	52.79 million	50.27 million	Optionable

KZR, NMRA, SCPH, and RAPT Headlines

Recent News About These Companies

With 42% stake, scPharmaceuticals Inc. (NASDAQ:SCPH) seems to have captured institutional investors' interest

June 12, 2025 | finance.yahoo.com

Nuveen Asset Management LLC Has $320,000 Position in scPharmaceuticals Inc. (NASDAQ:SCPH)

June 6, 2025 | marketbeat.com

BNP Paribas Financial Markets Increases Stake in scPharmaceuticals Inc. (NASDAQ:SCPH)

May 29, 2025 | marketbeat.com

Woodline Partners LP Sells 203,808 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH)

May 28, 2025 | marketbeat.com

scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025

May 22, 2025 | seekingalpha.com

scPharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

May 16, 2025 | finance.yahoo.com

scPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2025 Earnings Call Transcript

May 16, 2025 | insidermonkey.com

ScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectory

May 16, 2025 | msn.com

ScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectory

May 16, 2025 | msn.com

Q1 2025 scPharmaceuticals Inc Earnings Call

May 16, 2025 | finance.yahoo.com

Q1 2025 scPharmaceuticals Inc Earnings Call

May 16, 2025 | finance.yahoo.com

Why scPharmaceuticals Inc.’s (SCPH) Stock Is Up 18.30%

May 16, 2025 | aaii.comA

Why scPharmaceuticals Inc.’s (SCPH) Stock Is Up 18.30%

May 16, 2025 | aaii.comA

scPharmaceuticals Inc. (SCPH) Q1 2025 Earnings Call Transcript

May 15, 2025 | seekingalpha.com

ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates

May 14, 2025 | zacks.com

scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025 | globenewswire.com

Insights Ahead: scPharmaceuticals's Quarterly Earnings

May 13, 2025 | benzinga.com

Why scPharmaceuticals Inc.’s (SCPH) Stock Is Up 5.24%

May 7, 2025 | aaii.comA

scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025

May 7, 2025 | globenewswire.com

Why scPharmaceuticals Inc.’s (SCPH) Stock Is Down 5.85%

May 6, 2025 | aaii.comA

scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences

May 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZR, NMRA, SCPH, and RAPT Company Descriptions

Kezar Life Sciences NASDAQ:KZR

$4.44 +0.17 (+3.98%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.44 0.00 (0.00%)

As of 06/27/2025 04:04 PM Eastern

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Neumora Therapeutics NASDAQ:NMRA

$0.76 -0.04 (-5.32%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.80 +0.05 (+6.35%)

As of 06/27/2025 07:46 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Rapt Therapeutics NASDAQ:RAPT

$8.43 -1.30 (-13.36%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.17 -0.26 (-3.08%)

As of 06/27/2025 06:58 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

scPharmaceuticals NASDAQ:SCPH

$3.87 -0.11 (-2.76%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.92 +0.05 (+1.42%)

As of 06/27/2025 07:33 PM Eastern

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time